Physicians' Academy for Cardiovascular Education

Translation of novel approaches in CVD & diabetes to clinical practice

Expert Meeting on CVD & T2DM

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop
Three cardiology and diabetes experts consider how the paradigma-shifting recent insights on the new antidiabetic drug classes can be implemented into clinical practice, which should involve a more multidisciplinary approach.

Three cardiology and diabetes experts consider how the paradigma-shifting recent insights on the new antidiabetic drug classes can be implemented into clinical practice, which should involve a more multidisciplinary approach.

Novel diabetes drugs in clinical management: Extending the opportunities

Expert Meeting on CVD & T2DM

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe
Three cardiology and diabetes experts speculate on how GLP-1 RAs and SGLT2 inhibitors may be benefitted from to lower CV risk, beyond treatment of T2DM patients. Also; may they be used simultaneously?

Three cardiology and diabetes experts speculate on how GLP-1 RAs and SGLT2 inhibitors may be benefitted from to lower CV risk, beyond treatment of T2DM patients. Also; may they be used simultaneously?

Clinical trials in diabetes and CVD: What did we learn?

Expert Meeting on CVD & T2DM

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya
Filippo Crea, Angelyn Bethel and Eduard Montanya discuss the safety and efficacy results of recent trials evaluating GLP-1 RAs and SGLT2 inhibitors, and whether the observed effects represent a class effect or not.

Filippo Crea, Angelyn Bethel and Eduard Montanya discuss the safety and efficacy results of recent trials evaluating GLP-1 RAs and SGLT2 inhibitors, and whether the observed effects represent a class effect or not.

What are the key mechanisms of CV benefit of novel diabetes drugs?

Expert Meeting on CVD & T2DM

10' education - May 1, 2018 - Lina Badimon, Jochen Seufert, Naveed Sattar
Three cardiology and diabetes experts discuss what can be learned from trial results about mechanisms underlying the CV benefits seen with the novel antidiabetic drugs, and which questions remain unanswered.

Three cardiology and diabetes experts discuss what can be learned from trial results about mechanisms underlying the CV benefits seen with the novel antidiabetic drugs, and which questions remain unanswered.

What is the science driving CVD and T2DM?

Expert Meeting on CVD & T2DM

10' education - Mar. 22, 2018 - Wouter Jukema, Stephan Jacob, Ulf Landmesser
Three cardiology and diabetes experts discuss the multifactorial aspect of type 2 diabetes, and the consequential challenges in cardiovascular prevention and management.

Three cardiology and diabetes experts discuss the multifactorial aspect of type 2 diabetes, and the consequential challenges in cardiovascular prevention and management of these patients.